METHODS: Adults with UCC recorded cough measures at baseline and after completing 2 weeks of daily VTS. Feasibility and acceptability were assessed through participant-reported device use and structured feedback. Cough-related quality of life measures were the Leicester Cough Questionnaire (LCQ) and the Newcastle Laryngeal Hypersensitivity Questionnaire (NLHQ).
RESULTS: Nineteen adults participated, with mean age 67 years and cough duration 130 months. Notably, 93% of planned VTS sessions were logged, 94% of participants found the device comfortable to wear, 89% found it easy to operate and 79% would recommend it to others. Pre-post LCQ change achieved a minimal important difference (MID) (mean 1.3 [SD 2.4, p = 0.015]). NLHQ scores improved, but did not reach an MID.
CONCLUSIONS: Laryngeal VTS use was feasible and acceptable for use by patients with UCC and was associated with a meaningful improvement in cough-related quality of life. Future studies will include VTS dose refinement and the inclusion of a comparison arm to further assess the potential for laryngeal VTS as a novel treatment modality for UCC.
METHODS: 4 Laryngoscope, 2024.
方法:患有UCC的成年人在基线和完成2周的每日VTS后记录咳嗽测量值。通过参与者报告的设备使用情况和结构化反馈来评估可行性和可接受性。咳嗽相关的生活质量指标是莱斯特咳嗽问卷(LCQ)和纽卡斯尔喉敏感性问卷(NLHQ)。
结果:19名成年人参加,平均年龄67岁,咳嗽持续时间130个月。值得注意的是,已记录了93%的计划VTS会话,94%的参与者发现该设备佩戴舒适,89%的人发现它易于操作,79%的人会推荐给其他人。术后LCQ变化达到最小的重要差异(MID)(平均值1.3[SD2.4,p=0.015])。NLHQ得分提高,但没有达到一个MID。
结论:喉部VTS的使用对于UCC患者是可行和可接受的,并且与咳嗽相关生活质量的显著改善相关。未来的研究将包括VTS剂量细化和纳入比较臂,以进一步评估喉部VTS作为UCC新治疗方式的潜力。
方法:4喉镜,2024.